期刊文献+

紫杉醇脂质体联合铂类化疗同步放疗治疗宫颈癌的疗效分析 被引量:11

下载PDF
导出
摘要 目的研究紫杉醇脂质体联合铂类同步放化疗治疗宫颈癌近期疗效。方法选取2011年3月~2013年9月在本院接受诊治并确诊为宫颈癌的146名患者,随机分为研究组和对照组,各73例,对照组患者采用博来霉素、异环磷酰胺、顺铂BIP治疗方案,研究组采用紫杉醇脂质体联合铂类PT同步放化疗治疗方案,比较分析两组患者治疗效果。结果研究组宫颈癌总治疗有效率(75.34%)显著高于对照组(56.15%);且研究组消化系统、骨髓抑制等毒副作用均低于对照组,Ⅲ度、Ⅳ度阶段差异显著,两组比较差异具有统计学意义(P<0.05)。结论紫杉醇脂质体联合铂类化疗同步放疗方对女性宫颈癌治疗效果确切,毒副作用少。
出处 《中国处方药》 2014年第4期59-60,共2页 Journal of China Prescription Drug
  • 相关文献

参考文献3

二级参考文献26

  • 1宋水勤,张国楠.宫颈癌新辅助化疗现状[J].实用医院临床杂志,2005,2(2):22-25. 被引量:53
  • 2许彩芹,崔金全.紫杉醇在宫颈癌新辅助化疗中的应用[J].国外医学(妇幼保健分册),2005,16(6):413-415. 被引量:25
  • 3赵淑萍,王泽华.紫杉醇联合顺铂用于局部晚期宫颈癌新辅助化疗近期疗效观察[J].华中医学杂志,2006,30(1):43-44. 被引量:21
  • 4卞美璐.WHO(2006年)宫颈癌综合防治实践指南简介[J].中国实用妇科与产科杂志,2007,23(7):557-560. 被引量:106
  • 5PARK D C,KIM J H,LEW Y O,et al.Phase Ⅱ trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer[J].Gynecol Oncol,2004,92(1):59-63.
  • 6SARDI J,SANANES C,GIAROLI A,et al.Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri[J].Gynecol Oncol,1990,38(3):486-493.
  • 7CHEN H J,LIANG C,ZHANG L,et al.Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer:randomized study[J].Gynecol Oncol,2008,110(3):308-315.
  • 8曹泽毅.中华妇产科学[M].2 版.北京:人民卫生出版社,2004:1917-1918.
  • 9FRIEDLANDER M,KAYE S B,SULLIVAN A,et al.Cervical carcinoma:a drug-responsive tumour-experience with combined cisplatin,vinblastine,and bleomycin therapy[J].Gynecol Oncol,1983,16(2):275-281.
  • 10CHO Y H,KIM D Y,KIM J H,et al.Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer[J].J Gynecol Oncol,2009,20(1):22-27.

共引文献57

同被引文献107

  • 1张计华.用放疗联合同步多西紫杉醇+顺铂的化疗方案治疗中晚期宫颈癌的疗效观察[J].当代医药论丛,2014,12(12):241-242. 被引量:2
  • 2宋水勤,张国楠.宫颈癌新辅助化疗现状[J].实用医院临床杂志,2005,2(2):22-25. 被引量:53
  • 3魏梅,梁立治,袁颂华,颜笑健,杜佩妍,沈扬.宫颈腺癌105例临床病例分析[J].中国肿瘤临床,2005,32(21):1227-1230. 被引量:14
  • 4孙燕.内科肿瘤学[M].北京:人民卫生出版社,2006:102.
  • 5Han S, Li L, Jia X, et al. A molecular beacon based method for screening cervical cancer [ J ]. J Nanosei Nanotechnol, 2012, 12 (11) : 8282-8286.
  • 6Hirabayashi K, Ito J, Kobayashi M, et al. Taxol in advanced cer- vical cancer [ J ]. Nippon Rinsho, 2004, 62 ( Suppl 10 ) : 179 -182.
  • 7Cao X,Zhang L,Feng GR.et al.Preoperative cylVa21-l and SCC-Ag serum titers predict survival in patients with stage 11 esophageal squamous cell carcinoma[J].J Transl Med,2012,10:197.
  • 8Liu L,Liu B,Zhu LL,et al.Clinical significance of CYFRA21-1.SecAg and telomerase activity in serum and pleural effusion of patients with squamous-cell lung cancer[J].Bioanalysis,2012,4(19):2367-2374.
  • 9Tharavichitkul E,Sivasomboun C,Wanwilairat S,et al.Preliminary results of MRI-guided brachytherapy in cervical carcinoma:The Chiangmai university experience[J].J Rad Res,2012.53(2):313-318.
  • 10Assnholt MS, Vesiergaard A, Kallehauge J, et al. Proof of princi- ple: applicator-guided stereotactic IMRT boost in combination with 3D MRI-based braehytherapy in locally advanced cervical cancer[ J]. Brachytherapy,2014,16 (7) :342-355.

引证文献11

二级引证文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部